MEDINOL LTD.

ACTIVE

Kiryat Atidim Building 8, Tel Aviv-Jaffa, Central District, Israelwww.medinol.comPrivate251–500 employeesEstablished: 1992-12-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1992

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

58.8%

Phase 2

5.9%

Phase 4

5.9%

Trial Status Distribution

Active, not recruiting

5.9%

Completed

76.5%

Recruiting

5.9%

Suspended

5.9%

Terminated

5.9%

Clinical Trials

Trials sponsored by this organization (17)

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Not Applicable

Suspended

interventional

Aug 202530 participants

First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease

Not Applicable

Recruiting

interventional

Aug 202430 participants

IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Not Applicable

Active, not recruiting

interventional

Aug 202260 participants

BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial

Completed

observational

Dec 202081 participants

ChampioNIR® SFA Stent EFS Study

Not Applicable

Terminated

interventional

Oct 201922 participants

EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

Completed

observational

May 2019319 participants

BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

Not Applicable

Completed

interventional

Nov 201850 participants

MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)

Not Applicable

Completed

interventional

Jan 2017104 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations